Press Releases

Warminster, PA – L.B. Bohle, a longstanding manufacturer and supplier of high-quality processing solutions for pharmaceutical solids, will showcase a first-of-its-kind truly continuous granulator and dryer at INTERPHEX NYC, April 1-3. At Booth 1519A, the company will offer technical...

Qureight Ltd, the Core Imaging Laboratory developing deep-learning image analytics, and Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on developing inhaled therapies to treat life-threatening pulmonary diseases, today announce the initiation of a strategic partnership in progressive pulmonary fibrosis, commencing with the ongoing MIST study, a Phase...

Dublin, Ireland and Mumbai, India | London, U.K: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) and Glenmark Pharmaceuticals Limited (Glenmark), a global research-led pharmaceutical company, today announced that Glenmark had received approval from the Medicines and Healthcare products...

McKesson Corporation has announced its agreement to acquire a controlling 80% interest in PRISM Vision Holdings, LLC, investing approximately $850 million to expand its leadership in retina and ophthalmology care. PRISM Vision, a leading provider of general ophthalmology and...

Thermo Fisher Scientific Inc., the global leader in serving science, has announced the launch of the international CorEvitas Adolescent Alopecia Areata (AA) Registry. This initiative addresses a significant unmet need for real-world, adolescent-specific data on alopecia areata, an autoimmune...

Thermo Fisher Scientific has taken a significant step toward achieving its sustainability goals by signing a 10-year virtual power purchase agreement (VPPA) with renewable energy developer X-ELIO. This agreement supports the Lorca solar project, which is set to become...

The New England Journal of Medicine has published detailed findings from Roche’s Phase III REGENCY trial, which demonstrated the superiority of Gazyva®/Gazyvaro® (obinutuzumab) in combination with standard therapy for treating active lupus nephritis (LN). The trial shows a compelling...